Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Vanguard International High Dividend Yield ETF trades at $104.78. Which is the better fit depends on your goals.
| CRL | VYMI | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $282.00 | $105.05 |
52-Week Low | $145.57 | $82.92 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.59 with a neutral daily change. Technical indicators show a bullish trend from moving averages, though oscillators are neutral to slightly overbought. The fund has gained attention for its income appeal, with a 3.4% dividend yield and strong performance, including a 55% total return since prior coverage, as noted by Seeking Alpha on 2026-08-02. Recent institutional buying, such as by Barry Investment Advisors on 2026-08-10, underscores confidence.
The outlook is positive, driven by global diversification and high dividend growth, with Vanguard projecting international stocks to outperform U.S. equities over the next decade. Risks include currency fluctuations and economic volatility in international markets. Analyst sentiment is bullish, supported by the fund's defensive yield and institutional inflows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
